Video: Experts on why newer anticoagulants better for NVAF despite no antidote

Cardiologists Dr Jordan Fulcher, Dr Bradley Wilsmore and Dr Peter Blombery explain why patients with non-valvular atrial fibrillation (NVAF) could fare better with novel oral anticoagulants (NOACs) than with warfarin, despite no available antidote.